A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Condition:   Healthy Interventions:   Drug: QL0605;   Drug: US Neulasta Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting

Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials